Lupin Financial and Company Overview
Lupin Today
Operating from a Position of Strength
Global Presence
12th
Local Leadership
Largest Generic
3rd
Company
(by sales¹)
Largest in
the US
6th
(by prescriptions³)
lool
$2 bn
Annual sales in FY23
$233 mn
EBITDA in FY23
21,300+
Lupinytts
Reaching lives in
100+ countries
Geographically Diverse
(FY23 Sales)
LUPIN
India Pharma
Market Rank
37%
INDIA
8%
Developed
Markets
(by sales³)
4th
Largest
Australia
Gx
South Africa
8th
32%
US
14%
Gx
(by sales)
(by sales)
Emerging
7%
Developing
Adjacencies
Markets
API
With Global Infrastructure
And Growing Sustainably²
>10% reduction in Scope 1
15
Manufacturing
R&D
7
Sites
Sites
Renewable energy
across India, the US, Netherlands,
share of 6.5%
Brazil and Mexico
1 - Global ranking based on CY2022 sales | 2 FY23 Preliminary evaluation |3 IQVIA Qtr Mar-23
| 4-IQVIA MAT Mar-23
-
| 5 IQVIA MAT Feb-23
and 2 emissions
Adding 22MW
Renewable energy
capacity in FY24
4View entire presentation